SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-012668
Filing Date
2022-05-16
Accepted
2022-05-16 16:56:16
Documents
71
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20220331_10q.htm   iXBRL 10-Q 914694
2 EXHIBIT 31.1 ex_374870.htm EX-31.1 9117
3 EXHIBIT 31.2 ex_374871.htm EX-31.2 9137
4 EXHIBIT 32.1 ex_374872.htm EX-32.1 4720
5 EXHIBIT 32.2 ex_374873.htm EX-32.2 4745
  Complete submission text file 0001437749-22-012668.txt   5439226

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20220331.xsd EX-101.SCH 58210
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20220331_cal.xml EX-101.CAL 37350
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220331_def.xml EX-101.DEF 451356
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220331_lab.xml EX-101.LAB 340499
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220331_pre.xml EX-101.PRE 469801
65 EXTRACTED XBRL INSTANCE DOCUMENT navb20220331_10q_htm.xml XML 675821
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 22930429
SIC: 2835 In Vitro & In Vivo Diagnostic Substances